162 results
Page 8 of 9
6-K
EX-99.6
4au4 aoqt
27 Mar 19
Securities Purchase Agreement
8:32am
6-K
3gwhyj2 5r
27 Mar 19
Securities Purchase Agreement
8:32am
6-K
EX-99.2
urwql
19 Feb 19
Asset Purchase Agreement
4:57pm
6-K
EX-99.1
iw1 ql1vc
19 Feb 19
Asset Purchase Agreement
4:57pm
6-K
EX-99.2
zipz8t0
6 Dec 18
Amended Notice of Annual and Extraordinary General Meeting of the Shareholders
4:43pm
6-K
EX-99.1
5ut3fzat
19 Nov 18
Agreement and Plan of Merger
4:34pm
6-K
EX-99.1
qqidlceppo5q2
24 Oct 16
Bioblast Announces Results of Trehalose Clinical Study
12:00am
424B5
e2iiqx
18 Mar 16
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
4624y uds6k
27 Oct 15
Current report (foreign)
12:00am
6-K
EX-99.2
f893ue ic4a9twdh
27 Oct 15
Current report (foreign)
12:00am
6-K
9rxi81
27 Oct 15
Current report (foreign)
12:00am
20-F
ut70ohpz
31 Mar 15
Annual report (foreign)
12:00am
6-K
EX-99.1
jyaz7
8 Jan 15
Current report (foreign)
12:00am
6-K
EX-99.1
8rclni1gk 8h0f
21 Nov 14
Bio Blast Pharma Reports Third Quarter Financial Results
12:00am
6-K
EX-99.1
kfcki28y8y3d iu0zo
22 Sep 14
Bio Blast Pharma Announces Initiation of its Canadian OPMD Clinical Study Center at McGill University, Montreal
12:00am
6-K
EX-99.1
hx49izh htwod4buo7vz
17 Sep 14
BioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results with Cabaletta, Interim Safety Results from Phase 2/3HOPEMD Study in OPMD
12:00am
6-K
wbx1l5pslvykjwj1
17 Sep 14
BioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results with Cabaletta, Interim Safety Results from Phase 2/3HOPEMD Study in OPMD
12:00am